St. Jude’s FAME II FFR Study Successful, But Impact Is Debated
This article was originally published in The Gray Sheet
Executive Summary
Final results from the firm’s FAME II trial show the benefits of fractional flow reserve technology as an aid to patient selection for cardiac stenting, but because no heart attack or mortality reduction was found, the significance of the data is disputed.
You may also be interested in...
ACC 2017: Trial Shows FFR-Guidance Can Help Heart Attack Patients Avoid More Revascularizations
Results of the Compare-Acute trial show that STEMI patients benefit from complete revascularization guided by fractional flow reserve measurement, but most of this benefit was driven by the reduction in repeat revascularization. Investigators say more research will be needed to determine if this approach can reduce mortality or other "hard" endpoints.
Meta-analysis Confirms That Stents Do Not Extend Life In Stable Patients
Percutaneous coronary intervention with medical therapy does not reduce the risk of death, myocardial infarction or the need for unplanned revascularization procedures compared with medical therapy alone, a meta-analysis of five studies confirms.
TCT Conference In Brief
Clinical data news from the Transcatheter Cardiovascular Therapeutics conference held last week in Miami.